In yesterday’s Wall Street session, Angion Biomedica Corp. (NASDAQ:ANGN) shares traded at $0.70, up 9.32% from the previous session.
1 analysts cover Angion Biomedica Corp. (NASDAQ:ANGN), according to research data. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $1.50 and a low of $1.50, we find $1.50. Given the previous closing price of $0.64, this indicates a potential upside of 134.38 percent. ANGN stock price is now -16.77% away from the 50-day moving average and -37.83% away from the 200-day moving average. The market capitalization of the company currently stands at $22.11M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
The stock has received a hold rating from 1 analysts and a buy rating from 0. Brokers who have rated the stock have averaged $1.50 as their price target over the next twelve months.
With the price target of $40, Stifel recently initiated with Buy rating for Angion Biomedica Corp. (NASDAQ: ANGN). On March 02, 2021, Oppenheimer recently initiated its ‘Outperform’ rating on the stock quoting a target price of $38, while ‘Cowen’ rates the stock as ‘Outperform’.
In other news, Venkatesan Jay, insider bought 11,313 shares of the company’s stock on May 25. The stock was bought for $14,103 at an average price of $1.25. Upon completion of the transaction, the insider now directly owns 1,891,947 shares in the company, valued at $1.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 24, See Remarks Venkatesan Jay bought 32,200 shares of the business’s stock. A total of $39,928 was incurred on buying the stock at an average price of $1.24. This leaves the insider owning 1,721,457 shares of the company worth $1.21 million. Insiders disposed of 32,082 shares of company stock worth roughly $22457.399999999998 over the past 1 year. A total of 5.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ANGN stock. A new stake in Angion Biomedica Corp. shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $10,000. HIGHTOWER ADVISORS, LLC invested $9,000 in shares of ANGN during the first quarter. In the first quarter, MAN GROUP PLC acquired a new stake in Angion Biomedica Corp. valued at approximately $9,000. Y-INTERCEPT (HONG KONG) LTD acquired a new stake in ANGN for approximately $8,000. AMALGAMATED FINANCIAL CORP. purchased a new stake in ANGN valued at around $3,000 in the second quarter. In total, there are 58 active investors with 17.10% ownership of the company’s stock.
On Thursday morning Angion Biomedica Corp. (NASDAQ: ANGN) stock kicked off with the opening price of $0.6400. During the past 12 months, Angion Biomedica Corp. has had a low of $0.59 and a high of $2.94. As of last week, the company has a debt-to-equity ratio of 0.01, a current ratio of 6.90, and a quick ratio of 6.90. The fifty day moving average price for ANGN is $0.8411 and a two-hundred day moving average price translates $1.1259 for the stock.
The latest earnings results from Angion Biomedica Corp. (NASDAQ: ANGN) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.3, beating analysts’ expectations of -$0.46 by 0.16. This compares to -$0.53 EPS in the same period last year. The net profit margin was -61.90% and return on equity was -27.00% for ANGN. For the current quarter, analysts expect ANGN to generate $860k in revenue.
Angion Biomedica Corp.(ANGN) Company Profile
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company’s lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York.
